Fundz

Watching AbCellera Biologics Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Other EventsItem 8.01 · 8-KLOW RiskPositive

AbCellera Biologics Inc.

abcellera.com
Filed: Jul 29, 2026Vancouver, ArizonaCIK: 0001703057Health Care
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

AbCellera Biologics announced a strategic collaboration with Vertex Pharmaceuticals to jointly research, develop, manufacture, and commercialize multispecific T-cell engagers for autoimmune diseases, leveraging AbCellera's proprietary platform for discovery and early development.

Key Takeaways

AbCellera has secured a major partnership with Vertex Pharmaceuticals, a large pharmaceutical company, validating its T-cell engager platform technology

The collaboration focuses on multispecific T-cell engagers targeting autoimmune diseases and other conditions, expanding AbCellera's therapeutic reach

2 more takeaways

Related Filings (5)

5 more filings from AbCellera Biologics Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateJul 29, 2026
Item8.01
CategoryOther Events
CIK0001703057
Accession #abcl-20260729
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
partnershipmaterial agreement

What This Means

Other material events not covered by specific item numbers. The content of the filing determines significance.
View Full Filing on SEC.govBrowse More Filings

AbCellera Biologics Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.